What is MaxCyte's operating cash flow?

MaxCyte (MXCT) reported operating cash flow of -$8.17M in Q1 2026.

How has MaxCyte's operating cash flow changed year-over-year?

MaxCyte's operating cash flow increased by 43.3% year-over-year, from -$14.41M to -$8.17M.

What is the long-term trend for MaxCyte's operating cash flow?

Over 4 years (2021 to 2025), MaxCyte's operating cash flow has grown at a 34.0% compound annual growth rate (CAGR), from -$10.68M to -$34.41M.

What does operating cash flow mean?

Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

MaxCyte MXCT Operating Cash Flow

Operating Cash Flow at other companies

Bio-Rad LaboratoriesBIO

$108.1M-16.8%

Thermo Fisher ScientificTMO

$1.19B+64.9%

Ginkgo BioworksDNA

-$46.69M+9.4%

Immix Biopharma, Inc.IMMX

-$9.83M-483%

Rapid Micro BiosystemsRPID

-$15.06M-66.1%

PDE

Pro-Dex, Inc.PDEX

$1.63M+488%

Other financials

Income statement

See full

Revenue$9.7M-7.1%

Gross profit$8.1M-9.1%

Operating income-$6.2M+49.7%

Net income-$4.8M+53.7%

EPS (diluted)-$0.04+60.0%

Balance sheet

See full

Cash & equivalents$14.6M-37.8%

Total debt$17.5M-7.1%

Total equity$167.9M-15.8%

Total assets$194.5M-15.4%

Cash flow

See full

CapEx$72.0K-89.0%

Free cash flow-$8.2M+45.3%

Valuation

See full

Market cap$130.15M-46.8%

Enterprise value$133.08M-46.3%

P/S4×-2.8×

Profitability

See full

Gross margin80.5%-0.4pp

Operating margin-141.8%+6.4pp

Net margin-121.2%+12.3pp

FCF margin-90.9%+3.7pp

Returns & leverage

See full

Return on equity-21.3%+2.0pp

Debt / equity0.1×0.0×

Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MaxCyte's operating cash flow?: MaxCyte (MXCT) reported operating cash flow of -$8.17M in Q1 2026.
How has MaxCyte's operating cash flow changed year-over-year?: MaxCyte's operating cash flow increased by 43.3% year-over-year, from -$14.41M to -$8.17M.
What is the long-term trend for MaxCyte's operating cash flow?: Over 4 years (2021 to 2025), MaxCyte's operating cash flow has grown at a 34.0% compound annual growth rate (CAGR), from -$10.68M to -$34.41M.
What does operating cash flow mean?: Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.